M. García-Bernal , R. Cilveti , M. Villa , J. Molina , R. Fernández-Delgado , I. Badell
{"title":"儿童急性淋巴母细胞白血病与唐氏综合征:SHOP/LAL-99和05方案分析","authors":"M. García-Bernal , R. Cilveti , M. Villa , J. Molina , R. Fernández-Delgado , I. Badell","doi":"10.1016/S1138-2074(10)70074-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objective</h3><p>Down syndrome bears a known predisposition to childhood leukemia. In regards to acute lymphoblastic leukemia (ALL), most international groups show poorer results when compared to non-Down patients.</p></div><div><h3>Patients and methods</h3><p>With this study we analyze the results obtained with Down syndrome patients and ALL younger than 18 years who were treated with SHOP (Spanish Pediatric Hematology and Oncology Societies) protocols for the past decade.</p></div><div><h3>Results</h3><p>Current data obtained from 1000 patients out of 32 centers confirm several aspects: those are related to acute leukemia showing clinical and biological low risk treats, thereof they may be categorized in low risk groups hence receive scheduled chemotherapy of moderate intensity. However, the number of infectious and toxic complications is greater than those for non-Down patients, therefore both overall survival (OS) and event free survival (EFS) are markedly affected.</p></div><div><h3>Conclusions</h3><p>The future aim is to optimize the knowledge on biological aspects of these leukemia, in order to determine those features to be acted upon to improve their outcome.</p></div>","PeriodicalId":101116,"journal":{"name":"Revista Médica Internacional sobre el Síndrome de Down","volume":"14 3","pages":"Pages 36-46"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1138-2074(10)70074-9","citationCount":"0","resultStr":"{\"title\":\"Leucemia aguda linfoblástica infantil y síndrome de Down: análisis de los protocolos SHOP/LAL-99 y 05\",\"authors\":\"M. García-Bernal , R. Cilveti , M. Villa , J. Molina , R. Fernández-Delgado , I. Badell\",\"doi\":\"10.1016/S1138-2074(10)70074-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and objective</h3><p>Down syndrome bears a known predisposition to childhood leukemia. In regards to acute lymphoblastic leukemia (ALL), most international groups show poorer results when compared to non-Down patients.</p></div><div><h3>Patients and methods</h3><p>With this study we analyze the results obtained with Down syndrome patients and ALL younger than 18 years who were treated with SHOP (Spanish Pediatric Hematology and Oncology Societies) protocols for the past decade.</p></div><div><h3>Results</h3><p>Current data obtained from 1000 patients out of 32 centers confirm several aspects: those are related to acute leukemia showing clinical and biological low risk treats, thereof they may be categorized in low risk groups hence receive scheduled chemotherapy of moderate intensity. However, the number of infectious and toxic complications is greater than those for non-Down patients, therefore both overall survival (OS) and event free survival (EFS) are markedly affected.</p></div><div><h3>Conclusions</h3><p>The future aim is to optimize the knowledge on biological aspects of these leukemia, in order to determine those features to be acted upon to improve their outcome.</p></div>\",\"PeriodicalId\":101116,\"journal\":{\"name\":\"Revista Médica Internacional sobre el Síndrome de Down\",\"volume\":\"14 3\",\"pages\":\"Pages 36-46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1138-2074(10)70074-9\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Médica Internacional sobre el Síndrome de Down\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1138207410700749\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Médica Internacional sobre el Síndrome de Down","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1138207410700749","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Leucemia aguda linfoblástica infantil y síndrome de Down: análisis de los protocolos SHOP/LAL-99 y 05
Introduction and objective
Down syndrome bears a known predisposition to childhood leukemia. In regards to acute lymphoblastic leukemia (ALL), most international groups show poorer results when compared to non-Down patients.
Patients and methods
With this study we analyze the results obtained with Down syndrome patients and ALL younger than 18 years who were treated with SHOP (Spanish Pediatric Hematology and Oncology Societies) protocols for the past decade.
Results
Current data obtained from 1000 patients out of 32 centers confirm several aspects: those are related to acute leukemia showing clinical and biological low risk treats, thereof they may be categorized in low risk groups hence receive scheduled chemotherapy of moderate intensity. However, the number of infectious and toxic complications is greater than those for non-Down patients, therefore both overall survival (OS) and event free survival (EFS) are markedly affected.
Conclusions
The future aim is to optimize the knowledge on biological aspects of these leukemia, in order to determine those features to be acted upon to improve their outcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
